FLT3 and acute myeloid leukemia: Phase III clinical trials are underway in newly diagnosed FLT3-mutated AML versus midostaurin (NCT03258931) and in R/R FLT3-mutated AML in association with chemotherapy versus chemotherapy alone (NCT03250338).